Aberrant methylation: Common in thymic carcinomas, rare in thymomas

Oncology Reports

Volumn 14, Issue 6, 2005, Pages 1621-1624

  Suzuki, Makoto ^a,b   Chen, Hong ^a   Shigematsu, Hisayuki ^c   Ando, Soichiro ^a   Iida, Tomohiko ^a,b   Nakajima, Takahiro ^a,b   Fujisawa, Takehiko ^b   Kimura, Hideki ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

CYFRA21 1; EGFR; HER2; KRAS; Methylation; Mutation; Thymic carcinoma; Tumor marker

Indexed keywords

CELL CYCLE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN; RAS PROTEIN; RASSF1 PROTEIN, HUMAN; REPRIMO PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; COMPARATIVE STUDY; DNA METHYLATION; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; SURVIVAL; THYMOMA;

ADULT; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DNA METHYLATION; FEMALE; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; THYMOMA; THYMUS NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 33644690393     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.6.1621     Document Type: Article

References (25)

1. Giaccone G: Treatment of malignant thymoma. Curr Opin Oncol 17: 140-146, 2005.
2. Johnson SB, Eng TY, Giaccone G and Thomas CR Jr: Thymoma: update for the new millennium. Oncologist 6: 239-246, 2001.
3. Henley JD, Cummings OW and Loehrer PJ Sr: Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 130: 222-224, 2004. (Pubitemid 38553631)
4. Takahashi E, Tateyama H, Akatsu H, et al: Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organization classification subtype and clinical stage of thymic epithelial tumors. Hum Pathol 34: 1253-1258, 2003. (Pubitemid 38018138)
5. Penzel R, Hoegel J, Schmitz W, et al: Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 105: 494-498, 2003. (Pubitemid 36578553)
6. Gazdar AF, Miyajima K, Reddy J, et al: Molecular targets for cancer therapy and prevention. Chest 125: 97S-101S, 2004. (Pubitemid 38648324)
7. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF and Minna JD: RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 64: 3137-3143, 2004. (Pubitemid 38581414)
8. Suzuki M, Toyooka S, Shivapurkar N, et al: Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene 24: 1302-1308, 2005. (Pubitemid 40313933)
9. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M and Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23: 1000-1004, 2004. (Pubitemid 38250946)
10. Suzuki M, Shigematsu H, Takahashi T, et al: Aberrant methylation of Reprimo in lung cancer. Lung Cancer 47: 309-314, 2005. (Pubitemid 40248735)
11. Hirabayashi H, Fujii Y, Sakaguchi M, et al: p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 73: 639-644, 1997. (Pubitemid 127483057)
12. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
13. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
14. Stephens P, Hunter C, Bignell G, et al: Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526, 2004.
15. Shigematsu H, Takahashi T, Nomura M, et a: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646, 2005.
16. Masaoka A, Monden Y, Nakahara K and Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485-2492, 1981. (Pubitemid 12228012)
17. Ando S, Suzuki M, Yamamoto N, Iida T and Kimura H: The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res 24: 1941-1946, 2004. (Pubitemid 38954614)
18. Suzuki M, Toyooka S, Miyajima K, et al: Alterations in the mitochondrial displacement loop in lung cancers. Clin Cancer Res 9: 5636-5641, 2003. (Pubitemid 37499485)
19. Shigematsu H, Suzuki M, Takahashi T, et al: Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer 113: 600-604, 2005. (Pubitemid 40038736)
20. Toyooka S, Suzuki M, Maruyama R, et al: The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 91: 771-774, 2004. (Pubitemid 39141639)
21. Suzuki M, Hao C, Takahashi T, et al: Aberrant methylation of SPARC in human lung cancers. Br J Cancer 92: 942-948, 2005. (Pubitemid 40462643)
22. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005. (Pubitemid 40425952)
23. Kurup A and Loehrer PJ Sr: Thymoma and thymic carcinoma: therapeutic approaches. Clin Lung Cancer 6: 28-32, 2004. (Pubitemid 39199283)
24. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin 23: 857-865, 2005. (Pubitemid 46224186)
25. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501, 2005.